Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Drug Profile

Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Alternative Names: 3GA platform - Idera; Gene-silencing oligonucleotides - Idera; GSO - Idera; Third generation antisense platform - Idera; TLR antagonists for B cell lymphomas - Idera Pharmaceuticals; TLR anti-sense oligonucleotides - Idera

Latest Information Update: 10 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Leiden University; National Cancer Institute (USA)
  • Class Anti-inflammatories; Antineoplastics; Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Apolipoprotein B inhibitors; Carrier protein modulators; DUX4 protein modulators; Gene silencing; Immunomodulators; MicroRNA inhibitors; PCSK9 protein inhibitors; RNA interference; Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists; Toll-like receptor antagonists; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Facioscapulohumeral muscular dystrophy; Interstitial cystitis; Ischaemia; Lupus nephritis; Uveitis
  • No development reported Autoimmune disorders; B cell lymphoma; Hypercholesterolaemia; Inflammation; Psoriasis

Most Recent Events

  • 02 Aug 2018 Suspended - Preclinical for Lupus nephritis, Uveitis, Ischaemia, Interstitial cystitis and Facioscapulohumeral muscular dystrophy in USA (unspecified route)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top